Cargando…

Safety and efficacy associated with single-fraction high-dose-rate brachytherapy in localized prostate cancer: a systematic review and meta-analysis

OBJECTIVE: Although single-fraction high-dose-rate brachytherapy (SFHDR) for localized prostate cancer has been tried in clinical trials, relevant medical evidence is currently lacking. It is necessary to systematically analyze the safety and efficacy of SFHDR. METHODS: Comprehensive and systematic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Hong, Dai, Jindong, Cao, Dehong, Wang, Minghao, Zhao, Jinge, Zeng, Yuhao, Xu, Nanwei, Xie, Yandong, Liu, Haolin, Zeng, Hao, Sun, Guangxi, Shen, Pengfei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212877/ https://www.ncbi.nlm.nih.gov/pubmed/37093230 http://dx.doi.org/10.1007/s00066-023-02063-z

Ejemplares similares

Primary renal mucinous adenocarcinoma masquerading as a giant renal cyst: a case report
por: Zeng, Hong, et al.
Publicado: (2023)

Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients
por: ZHU, SHA, et al.
Publicado: (2023)

The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis
por: Chen, Junru, et al.
Publicado: (2018)

The value of transperineal apical prostate biopsy in predicting urethral/apical margin status after radical prostatectomy
por: Dai, Jindong, et al.
Publicado: (2019)

The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis
por: Wang, Zhipeng, et al.
Publicado: (2020)

The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2023)

Retraction to the prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2023)

Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Zhu, Sha, et al.
Publicado: (2022)

MicroRNA-106a suppresses prostate cancer proliferation, migration and invasion by targeting tumor-derived IL-8
por: Shen, Pengfei, et al.
Publicado: (2020)

High-dose-rate fractionated brachytherapy monotherapy for localized prostate cancer: a systematic review and meta-analysis
por: Anderson, Eric M., et al.
Publicado: (2021)

Low dose rate prostate brachytherapy
por: Stish, Bradley J., et al.
Publicado: (2018)

The prognosis benefits of adjuvant versus salvage radiotherapy for patients after radical prostatectomy with adverse pathological features: a systematic review and meta-analysis
por: Tao, Ronggui, et al.
Publicado: (2019)

Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control
por: Mayrata, Esther, et al.
Publicado: (2021)

Survival Outcomes of Radical Prostatectomy + Extended Pelvic Lymph Node Dissection and Radiotherapy in Prostate Cancer Patients With a Risk of Lymph Node Invasion Over 5%: A Population-Based Analysis
por: Chen, Junru, et al.
Publicado: (2020)

Pulmonary Metastases After Low-Dose-Rate Brachytherapy for Localized Prostate Cancer
por: Kido, Masahito, et al.
Publicado: (2014)

High-dose-rate brachytherapy delivered in two fractions as monotherapy for low-risk prostate cancer
por: Cendales, Ricardo, et al.
Publicado: (2015)

Unexpected lower biochemical control of high-dose-rate brachytherapy boost than low-dose-rate brachytherapy boost for clinically localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2020)

A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
por: Hathout, Lara, et al.
Publicado: (2019)

Efficacy and Safety of High-Dose-Rate Brachytherapy of Single Implant with Two Fractions Combined with External Beam Radiotherapy for Hormone-Naïve Localized Prostate Cancer
por: Noda, Yasutaka, et al.
Publicado: (2011)

Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)
por: Zhu, Sha, et al.
Publicado: (2022)

Response to ‘Unexpected lower biochemical control of high-dose-rate brachytherapy boost than low-dose-rate brachytherapy boost for clinically localized prostate cancer’
por: Slevin, Finbar, et al.
Publicado: (2020)

High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2021)

Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature
por: Kunogi, Hiroaki, et al.
Publicado: (2016)

High dose-rate brachytherapy in the treatment of prostate cancer
por: Mendez, Lucas C., et al.
Publicado: (2018)

Exosomal TUBB3 mRNA expression of metastatic castration‐resistant prostate cancer patients: Association with patient outcome under abiraterone
por: Zhu, Sha, et al.
Publicado: (2021)

Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis
por: Chen, Junru, et al.
Publicado: (2022)

The oncologic and safety outcomes of low-dose-rate brachytherapy for the treatment of prostate cancer
por: Tanaka, Nobumichi
Publicado: (2023)

High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot
por: Keam, Simon P, et al.
Publicado: (2020)

Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2016)

Focal low-dose rate brachytherapy for the treatment of prostate cancer
por: Tong, William Y, et al.
Publicado: (2013)

Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma
por: Zhu, Xudong, et al.
Publicado: (2021)

Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer – between options
por: Skowronek, Janusz
Publicado: (2013)

Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer
por: Barnes, Justin, et al.
Publicado: (2019)

Prostate cancer boost using high-dose-rate brachytherapy: early toxicity analysis of 3 different fractionation schemes
por: Hijazi, Hussam, et al.
Publicado: (2013)

Measurement of craniocaudal catheter displacement between fractions in computed tomography–based high dose rate brachytherapy of prostate cancer
por: Kim, Yongbok, et al.
Publicado: (2007)

Patient and physician reported toxicity with two-fraction definitive high-dose-rate prostate brachytherapy: the impact of implant interval
por: Harris, Alexander A., et al.
Publicado: (2020)

A radiobiological study of the schemes with a low number of fractions in high-dose-rate brachytherapy as monotherapy for prostate cancer
por: Guirado, Damián, et al.
Publicado: (2020)

Re-salvage MRI-guided Focal High-dose-rate Brachytherapy for Locally Recurrent Prostate Cancer
por: Van Son, Marieke J, et al.
Publicado: (2018)

Single-fraction image-guided high-dose-rate brachytherapy for head and neck cancer: three cases of palliative brachytherapy
por: Ota, Yoshiaki, et al.
Publicado: (2020)

High-dose-rate brachytherapy boost for prostate cancer: rationale and technique
por: Morton, Gerard C.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5fcqj5uaopivrdn4c5q2el76fb